Industry Symposia


Sunday, 25 April

11:30 a.m. – 12:30 p.m. EDT


Non-CME Industry Symposium offered by CareDx - HeartCare: The Utility of Multi-Modality in Transplant Patient Care

Join us for a discussion on HeartCare, the combination of AlloMap and AlloSure Heart, including the evolution of patient specific biomarkers, data supporting utility in CMV and CAV, and patient case studies.

Sham Dholakia, MD, DPhil-MD, CareDx, Inc, South San Francisco, CA
Mario Deng, MD, FACC, FESC, UCLA, Los Angeles, CA
Brett Sperry, MD, St. Luke’s Mid-America Heart Institute, Kansas City, MO
Heddy Luise Holzhauser, MD, FACC, University of Pennsylvania, Pennsylvania, PA
Manreet Kanwar, MD, Allegheny General Hospital, Pittsburgh, PA

Non-CME Industry Symposium offered by Abiomed - Optimizing Outcomes with Impella 5.5® with SmartAssist®

Optimizing end-stage heart failure patients refractory to guideline directed medical therapy or continuous inotropes with temporary mechanical circulatory support.

Rohan Goswami, MD, Mayo Clinic Jacksonville, Jacksonville, FL, USA

Jacob Schroder, MD, Duke University Medical Center, Durham, NC, USA
Dominic Emerson, MD, Cedars-Sinai Medical Center, Los Angeles, CA, USA
Basar Sareyyupoglu, MD, Mayo Clinic Jacksonville, Jacksonville, FL, USA

2:30 p.m. – 3:30 p.m. EDT

Non-CME Industry Symposium offered by Altavant Sciences - Serotonin Pathobiology in Pulmonary Arterial Hypertension (PAH) and Phase 2b Investigation of the Novel Therapy Rodatristat Ethyl (RE) in WHO Group 1 PAH

Altavant Sciences corporate and pipeline overview, expert review of the serotonin hypothesis in pulmonary hypertension, rodatristat ethyl mechanism of action and phase 2b clinical investigation of the safety and efficacy of rodatristat ethyl in PAH.

Bill Symonds, PharmD, Altavant Sciences-Chief Executive Officer
Howard M Lazarus, MD, FCCP, Altavant Sciences- Chief Medical Officer
Stephen Wring, PhD, Altavant Sciences- Vice President Research and Development
Marc Humbert, MD, PhD, Université Paris-Saclay, Le Kremlin-Bicêtre, France

Monday, 26 April

9:30 a.m. – 10:30 a.m. EDT

Non-CME Industry Symposium offered by CareDx - AlloSure Lung: Donor-Derived Cell-Free DNA as an Innovative Biomarker for Lung Transplant Patients

Join us for a discussion on AlloSure Lung donor-derived cell-free DNA, the first and only non-invasive solution for the surveillance lung transplant patients.

Sham Dholakia, MD, DPhil-MD, CareDx, Inc, South San Francisco, CA
Deborah Levine, MD; University of Texas Health Science Center, San Antonio, TX, USA
Kiran Khush, MD; Stanford University, Stanford, CA, USA
Sam Weigt, MD; UCLA Medical Center, Los Angeles, CA, USA
Pali Shah, MD; Johns Hopkins University, Baltimore, MD, USA
Brian Keller, MD, PhD, The Ohio State University College of Medicine, Columbus, OH, USA

10:45 a.m. – 11:45 a.m. EDT

Non-CME Industry Symposium offered by Abiomed - Hospital to Home: Walking and Talking on ECMO

The Abiomed Breethe OXY-1 System is an extracorporeal cardiopulmonary support system that can be used in both VA and VV configurations, delivering advanced gas exchange technology via its novel oxygenator design. It’s simple and intuitive to use, providing the unique ability to provide therapy to patients while allowing them to be mobile. Cannulation and ambulation strategies, patient selection, best practice guidelines, and ECMO Program experience will be covered during this interactive presentation.

Bart Griffith, MD, University of Maryland, College Park, MD, USA

Zachary Kon, MD, Northwell Medical Center, Manhasset, NY, USA
Si Pham, MD, Mayo Clinic Jacksonville, Jacksonville, FL, USA
Chris L. Wells, PhD, PT, CCS, ATC, University of Maryland, School of Medicine Department of Physical Therapy & Rehabilitation Sciences, Baltimore, MD, USA

Non-CME Industry Symposium offered by One Lambda, A Thermo Fisher Scientific Brand - Innovations in Rejection Surveillance after Heart Transplantation

For post-transplant management in heart patients, the endomyocardial biopsy is considered the gold standard to detect acute rejection. However, research has found that in biopsy assessments for rejection, concordance among expert pathologists is less than 67%. This presentation will explore case studies and the clinical use of novel technologies, including molecular diagnostic testing of intragraft mRNA transcripts and donor-derived cell-free DNA, for more accurate diagnosis of cellular and antibody-mediated rejection, acute rejection, and cardiac allograft vasculopathy (CAV).

Jon A. Kobashigawa MD, Cedars-Sinai Medical Center, Los Angeles, CA, USA

Tuesday, 27 April

12:45 p.m. – 1:45 p.m. EDT

Non-CME Industry Symposium offered by Abbott - A Fresh Perspective On Caring for Advanced Heart Failure Patients

This Abbott-sponsored industry symposium is led by 3 nationally recognized clinical experts in the field of Mechanical Circulatory Support (MCS). This unique program seeks to highlight fresh perspectives on Heart Failure and MCS therapy with a special emphasis on the timing of MCS, the challenges of managing MCS patients in the age of COVID, and updated surgical techniques for these life-saving devices. Abbott is committed to supporting advanced heart failure patients as they live life to the fullest.

Topics: * Timing of MCS: Insights from Quantifying Sarcopenia *Challenges in Heart Failure with a Focus on Mechanical Support during the COVID Pandemic * Surgical Approaches and Devices for durable MCS

Rebecca Cogswell, MD, University of Minnesota Division of Cardiology, Minneapolis, MN, USA
Anuradha Lala-Trindade (Anu Lala), MD, Mount Sinai Medical Center, New York, NY, USA
Marzia Leacche, MD, Spectrum Health Frederik Meijer Heart Center, Grand Rapids, MI, USA

2:00 p.m. – 3:00 p.m. EDT

Non-CME Industry Symposium offered by Natera - Next Generation Non-Invasive cfDNA Technology to Assess Post Transplant Organ Health

We invite you to join us for a presentation by Natera’s founder who will speak about our deep experience around cell free DNA. He will provide insights on how we are changing management of pregnancy, cancer and organ transplant with non-invasive DNA technology. This will be followed by a lively debate on the pros and cons of routine surveillance biopsies to detect rejection in heart transplant recipients.

Matthew Rabinowitz, PhD, Natera, Inc., San Carlos, CA, USA
Shelley Hall, MD, Baylor University Medical Center, Dallas, TX, USA
Eileen Hsich, MD, Cleveland Clinic, Cleveland, OH, USA

Wednesday, 28 April

2:00 p.m. – 3:00 p.m. EDT

Non-CME Industry Symposium offered by XVIVO Perfusion - Extending Horizons in Ex-vivo Lung Perfusion

The scarcity of donated organs suitable for transplantation remains a challenge in lung transplantation. This symposium will focus on three different topics related to the extended utilization of donated lungs and how Ex Vivo Lung Perfusion (EVLP) can be used to break-down some of the barriers.

Topics: * Experience with the first 50 EVLP’s in Groningen * Hôpital Foch's internal organisation and leadership in DCD program in France * Lung repair and regeneration using machine perfusion

Caroline Van De Wauwer, M.D., UMC Groningen, Groningen, The Netherlands
Julien de Wolf, M.D., Hôpital Foch, Paris, France
Prof. Sandra Lindstedt, Skane University Hospital, Lund, Sweden